First, while our in vitro data are compelling, in vivo validation using established PAH models such as the Sugen/hypoxia rat or monocrotaline-induced PAH model is necessary to assess the therapeutic potential of MELK inhibition in a physiologically relevant context. The gene discussed is MELK; the disease is pulmonary arterial hypertension.